HK38997A - Controlled release of macromolecular polypeptides - Google Patents

Controlled release of macromolecular polypeptides

Info

Publication number
HK38997A
HK38997A HK38997A HK38997A HK38997A HK 38997 A HK38997 A HK 38997A HK 38997 A HK38997 A HK 38997A HK 38997 A HK38997 A HK 38997A HK 38997 A HK38997 A HK 38997A
Authority
HK
Hong Kong
Prior art keywords
controlled release
macromolecular polypeptides
macromolecular
polypeptides
micro
Prior art date
Application number
HK38997A
Other languages
English (en)
Inventor
Deborah Ann Eppstein
Brian Bloor Schryver
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25348017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK38997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of HK38997A publication Critical patent/HK38997A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK38997A 1986-05-23 1997-03-27 Controlled release of macromolecular polypeptides HK38997A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/866,625 US4962091A (en) 1986-05-23 1986-05-23 Controlled release of macromolecular polypeptides

Publications (1)

Publication Number Publication Date
HK38997A true HK38997A (en) 1997-04-04

Family

ID=25348017

Family Applications (1)

Application Number Title Priority Date Filing Date
HK38997A HK38997A (en) 1986-05-23 1997-03-27 Controlled release of macromolecular polypeptides

Country Status (10)

Country Link
US (1) US4962091A (fr)
EP (1) EP0251476B2 (fr)
JP (1) JP2594560B2 (fr)
AT (1) ATE85214T1 (fr)
AU (1) AU608225B2 (fr)
CA (1) CA1293443C (fr)
DE (1) DE3783958T3 (fr)
ES (1) ES2039437T5 (fr)
HK (1) HK38997A (fr)
NZ (1) NZ220403A (fr)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH681425A5 (fr) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5597798A (en) * 1990-03-05 1997-01-28 The Regents Of The University Of California Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
US5252342A (en) * 1990-03-05 1993-10-12 The Regents Of The University Of California Enhancement of anti-neoplastic drug efficacy using EGF
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US6517859B1 (en) * 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
ATE226091T1 (de) * 1990-05-16 2002-11-15 Southern Res Inst Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
CA2046830C (fr) * 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
IL99497A (en) * 1990-10-01 1997-03-18 Res Dev Foundation Synergistic compositions comprising tnf and il-4
AU8934591A (en) * 1990-10-09 1992-04-28 Sri International Activated ctap and analogs thereof and their use
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU667462B2 (en) * 1990-11-30 1996-03-28 Monoclonetics International Incorporated Methods for the diagnosis of chronic lower back and cervical pain
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
DE69203443T2 (de) * 1991-01-16 1995-12-07 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
AU8303691A (en) * 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1993015722A1 (fr) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
CA2129514A1 (fr) * 1992-03-12 1993-09-16 M. Amin Khan Acth a liberation controlee, contenant des microspheres
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
AU3941793A (en) * 1992-03-30 1993-11-08 Alza Corporation Additives for bioerodible polymers to regulate degradation
MX9301823A (es) * 1992-03-30 1994-01-31 Alza Corp Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US7105158B1 (en) * 1992-11-16 2006-09-12 The Corporation Of Mercer University Methods of administering microencapsulated materials for immune modulated diseases
EP1013270A3 (fr) * 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Microsphères contenant une hormone de croissance à libération régulée
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
RU2143889C1 (ru) * 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
WO1994023699A1 (fr) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Traitement a action prolongee par apport a liberation lente d'oligodesoxyribonucleotides anti-sens a partir de microparticules biodegradables
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
EP0670733A1 (fr) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions contenant des facteurs de croissance et des agents antiplastiques
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
JPH07100178A (ja) * 1993-10-01 1995-04-18 Sadako Ueda 天然炭酸カルシウム入浴剤
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
AU8095694A (en) * 1993-10-28 1995-05-22 Thm Biomedical, Inc. Improved process and device for treating and healing a bone void
JPH09506866A (ja) * 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
ES2156932T3 (es) * 1993-12-23 2001-08-01 Rmf Dictagene Sa Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.
PT754032E (pt) * 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
US5981825A (en) 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
US5681568A (en) * 1994-08-19 1997-10-28 Cambridge Neuroscience, Inc. Device for delivery of substances and methods of use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
JPH08215516A (ja) * 1995-02-10 1996-08-27 Hiroshi Kaneko 浴槽水の浄化・活性化フィルタ−
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
EP0765660A3 (fr) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules contenant des acides 2-pipérazinone-1-yl-acétiques
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6902584B2 (en) 1995-10-16 2005-06-07 Depuy Spine, Inc. Bone grafting matrix
US5776193A (en) 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
DE69717263T2 (de) 1996-03-28 2003-07-24 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter freisetzung und deren herstellung
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
EP1037663A2 (fr) 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Procedes permettant de traiter des reponses immunitaires indesirables
DE69904701T2 (de) 1998-03-20 2003-11-06 Takeda Chemical Industries, Ltd. Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AU6027899A (en) * 1998-09-02 2000-03-21 Point Biomedical Corporation Local delivery of medications to the heart
CA2350638C (fr) 1998-09-11 2009-11-24 Gerhard Schmidmaier Implants biologiquement actifs recouverts d'un polymere biodegradable
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
EP1154760A1 (fr) * 1999-02-19 2001-11-21 Bioserv AG Materiaux composites biodegradables pour la fabrication de microcapsules
JP2002539172A (ja) * 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
ATE244558T1 (de) * 1999-04-16 2003-07-15 Novo Nordisk As Trockene formbare arzneistoffformulierung
DE19932603A1 (de) 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren
US7678087B2 (en) * 1999-09-29 2010-03-16 Heska Corporation Equine intranasal delivery system
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
CA2400319C (fr) 2000-03-15 2008-09-16 Orbus Medical Technologies Inc. Revetement favorisant la fixation des cellules endotheliales
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
ATE355813T1 (de) * 2000-07-14 2007-03-15 Novo Nordisk As Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
AU2002232824A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
CA2433361A1 (fr) * 2000-12-29 2002-07-11 Sidney Pestka Systemes a liberation regulee pour polymeres
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
CA2451187C (fr) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
DE10146251A1 (de) * 2001-09-20 2003-04-17 Gruenenthal Gmbh Vorrichtung zur Herstellung eines pharmazeutischen Films
MXPA04004726A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
EP1575481A4 (fr) 2002-03-01 2010-01-06 Celltech R & D Inc Procedes destines a accroitre ou a reduire la densite osseuse
PT2561860T (pt) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
WO2004004702A2 (fr) 2002-07-09 2004-01-15 The Scripps Research Institute Procede pour empecher les lesions par ischemie et reperfusion
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) * 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
WO2004045531A2 (fr) * 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection du myocarge cardiaque
EP1572976B1 (fr) 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulation de reponses immunitaires
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
US20070026069A1 (en) * 2003-03-28 2007-02-01 Shastri Venkatram P Biommetic hierarchies using functionalized nanoparticles as building blocks
CN102772357B (zh) * 2003-03-31 2014-12-31 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
WO2004098634A2 (fr) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Proteine arginine n-methyltransferase 2 (prmt-2)
CA2526099C (fr) * 2003-06-20 2013-02-05 Ares Trading Sa Formulations lyophilisees a base de fsh/lh
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses
JP2007504244A (ja) * 2003-09-05 2007-03-01 ザ スクリプス リサーチ インスティテュート アテローム硬化症および／または心血管性疾患の処置および予防のためのコレステロールのオゾン化産物
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US7164008B2 (en) * 2003-11-17 2007-01-16 University Of Iowa Research Foundation Isolated complexes of endotoxin and MD-2
JP2007527539A (ja) * 2004-03-05 2007-09-27 ザ スクリプス リサーチ インスティテュート ハイスループットグリカンマイクロアレイ
US8613934B2 (en) * 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
EP2946666B1 (fr) 2004-04-30 2017-11-15 OrbusNeich Medical, Inc. Dispositif médical avec revêtement permettant de capturer des cellules génétiquement modifiées et procédés d'utilisation de celui-ci
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7868158B2 (en) * 2004-07-19 2011-01-11 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
SG10201606278UA (en) 2004-08-18 2016-09-29 Novabiotics Ltd Peptide
WO2006068758A2 (fr) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention et traitement du cancer du sein
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US7413729B2 (en) * 2005-01-13 2008-08-19 University Of Iowa Research Foundation Sialic acid permease system
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
WO2007072037A1 (fr) 2005-12-22 2007-06-28 Novabiotics Limited Peptides cycliques antimicrobiens
EP1986676A4 (fr) * 2006-02-15 2009-11-04 Univ Yale Inc Compositions et procedes utilisant des fragments de peptide du facteur derive d'epithelium pigmentaire (pedf)
US8088396B2 (en) * 2006-03-01 2012-01-03 University Of Iowa Research Foundation Isolated complexes of endotoxin and modified MD-2
US20070265170A1 (en) * 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer
WO2008036838A2 (fr) * 2006-09-20 2008-03-27 University Of Iowa Research Foundation Complexes isolés d'endotoxine et de md-2 modifié à réticulation covalente
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
US8258286B2 (en) 2007-04-26 2012-09-04 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
IL268475B (en) 2007-05-31 2022-08-01 Government Of The Us Secretary Of The Department Of Health And Human Services National Institutes Of N-acetyl mannosamine as a medical preparation
EP2222344A4 (fr) * 2007-11-30 2012-11-07 Baylor College Medicine Compositions de vaccin à cellules dendritiques et utilisations de celles-ci
TWI352717B (en) 2007-12-11 2011-11-21 Ind Tech Res Inst A tenacity adjuster, a biodegradable material comp
WO2009089027A1 (fr) * 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Inhibiteurs de phosphodiestérase
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
AR067447A1 (es) * 2008-07-03 2009-10-14 Monte Verde S A Un procedimiento para preparar una composicion farmaceutica que contiene los proincipios activos glucosamina y meloxicam y el uso de dicha asociacion para el tratamiento de patologias degenerativas osteo-articulares
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8568363B2 (en) 2008-10-31 2013-10-29 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8551506B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100178038A1 (en) * 2009-01-12 2010-07-15 Mediatek Inc. Video player
US9808504B2 (en) 2009-09-22 2017-11-07 Yale University Immunogenic epitopes as targets for universal cancer vaccines
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
US8632839B2 (en) * 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
EP2468269A1 (fr) 2010-11-26 2012-06-27 Universitätsklinikum Münster Donneurs d'oxyde nitrique pour la thérapie des perturbations induites par une déficience d'oxyde nitrique de la microcirculation cérébrale
WO2012076842A1 (fr) 2010-12-09 2012-06-14 University Of Durham Rétinoïdes synthétiques pour le contrôle de la différenciation des cellules
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
WO2012109667A1 (fr) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Composés thérapeutiques
AU2012321317B2 (en) 2011-07-12 2016-01-28 Inovio Pharmaceuticals, Inc Novel clostridium difficile DNA vaccine
WO2013013178A1 (fr) 2011-07-21 2013-01-24 Kansas State University Research Foundation Sesquiterpènes pour applications antifongiques
WO2014011663A1 (fr) 2012-07-09 2014-01-16 Board Of Trustees Of Michigan State University Inhibiteurs de la bactérie diguanylate cyclase
CA2889020A1 (fr) 2012-10-23 2014-05-01 Cornell University Traitement du cancer du sein metastatique
CA2890258C (fr) * 2012-11-02 2020-10-20 Cytuvax Composition comprenant des macro-agregats de cytokine
EP2951199A4 (fr) 2013-01-31 2016-07-20 Univ Jefferson Protéines de fusion pour la modulation des lymphocytes t régulateurs et effecteurs
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
WO2015021415A1 (fr) 2013-08-09 2015-02-12 The Scripps Research Institute Conception dans le transcriptome de petites molécules bioactives sélectives ciblant l'arn
WO2015041809A2 (fr) 2013-08-26 2015-03-26 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Reprogrammation cellulaire par petites molécules pour générer des cellules neuronales
EP3043822A1 (fr) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions pour prépaprer des cardiomyocytes
CN107075514A (zh) 2014-05-20 2017-08-18 衣阿华大学研究基金会 亨廷顿氏病的治疗化合物
US10519443B2 (en) 2014-09-08 2019-12-31 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
US9758781B2 (en) 2014-09-30 2017-09-12 University Of Iowa Research Foundation Methods to prevent and treat autosomal dominant non-syndromic hearing loss
EP3261675A1 (fr) 2015-02-25 2018-01-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Thérapies d'augmentation de sialylation pour maladies associées au stress oxydatif
US11027024B2 (en) 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
US10682396B2 (en) 2015-06-09 2020-06-16 B.G. Negev Technologies And Applications Ltd Controlled release system for pulmonary delivery of surfactant protein D
US20190010451A1 (en) 2015-08-07 2019-01-10 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Chemical reprogramming to generate neuronal cells
EP3271452B1 (fr) * 2015-12-17 2021-12-08 Life Technologies Corporation Pastilles utilisées en culture cellulaire et leurs procédés de fabrication
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
US10994006B2 (en) 2016-07-08 2021-05-04 The Scripps Research Institute Desensitizing mast cells by co-presentation of antigens with high affinity mast cell siglec ligands
WO2018224813A1 (fr) 2017-06-06 2018-12-13 Novabiotics Limited Utilisation de compositions de cystéamine
US11154606B2 (en) 2017-07-05 2021-10-26 Arizona Board Of Regents On Behalf Of Arizona State University Vaccine for prevention of necrotic enteritis in poultry
EP3652349A1 (fr) 2017-07-10 2020-05-20 Cornell University Ciblage d'instabilité chromosomique et de signalisation d'adn cytosolique en aval pour le traitement du cancer
US11452764B2 (en) 2017-07-21 2022-09-27 University Of North Dakota Inhibiting FAK-AKT interaction to inhibit metastasis
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
CA3116637A1 (fr) 2018-10-17 2020-04-23 Novabiotics Limited Regime posologique
US20220089670A1 (en) 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
SG11202110607WA (en) 2019-04-01 2021-10-28 Tenaya Therapeutics Inc Adeno-associated virus with engineered capsid
EP3997226A1 (fr) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Reprogrammation de cellules cardiaques avec des microarn et d'autres facteurs
US20230037822A1 (en) 2019-10-28 2023-02-09 The Scripps Research Institute Immune cell receptor antibodies conjugated to high affinity siglec-ligands
WO2021142230A1 (fr) 2020-01-10 2021-07-15 Cornell University Méthodes pour modifier la latence dans des malignités ebv+
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
CN116997651A (zh) 2021-01-19 2023-11-03 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 用于增强人t细胞功能的基因激活靶标
WO2023250249A1 (fr) 2022-06-23 2023-12-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Inhibiteurs de hmgb1 pour le traitement de tauopathies associées à apoe4 comprenant la maladie d'alzheimer
WO2024097418A2 (fr) 2022-11-03 2024-05-10 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Cibles d'activation et d'interférence de gènes pour des produits de lymphocytes t résistants à l'épuisement/dysfonctionnement et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) * 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
CA1196864A (fr) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Composes d'insuline implantable et injectable a liberation regulee
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism

Also Published As

Publication number Publication date
ATE85214T1 (de) 1993-02-15
JP2594560B2 (ja) 1997-03-26
EP0251476A1 (fr) 1988-01-07
EP0251476B1 (fr) 1993-02-03
US4962091A (en) 1990-10-09
DE3783958T2 (de) 1993-06-09
AU608225B2 (en) 1991-03-28
AU7333287A (en) 1987-11-26
DE3783958T3 (de) 2003-08-07
DE3783958D1 (de) 1993-03-18
ES2039437T3 (es) 1993-10-01
CA1293443C (fr) 1991-12-24
ES2039437T5 (es) 2003-06-16
EP0251476B2 (fr) 2002-11-27
JPS632930A (ja) 1988-01-07
NZ220403A (en) 1990-06-26

Similar Documents

Publication Publication Date Title
HK38997A (en) Controlled release of macromolecular polypeptides
GB2185397B (en) Drug delivery system
DK288987A (da) Et afgivelsessystem til doseringsformerne forhalet afgivelse, samt dettes fremstilling
GB8712176D0 (en) Drug delivery system
GB8723846D0 (en) Bioadhesive microsphere drug delivery system
PH24331A (en) Drug delivery system
EP0184910A3 (en) Device for controlled release drug delivery
AU7211287A (en) Controlled release drug delivery system for the peridontal pocket
AU7183787A (en) Pulsed drug delivery
PT80525B (en) Sustained release drug delivery device
NO882897D0 (no) Avleveringssystem for legemidler.
IL87755A (en) Solubility modulated drug delivery device
IL82674A0 (en) Passive drug delivery system
MY102046A (en) Compartmentalized transdermal delivery system.
EP0246861A3 (en) Pharmaceutical composition based on crotoxine, process for preparing the active component and the pharmaceutical composition
AU8035491A (en) Controlled release drug delivery system for melatonin in goats
EP0408019A3 (en) Pharmaceutical active derivative delivery systems
AU1464588A (en) Sheep delivery system
IL80330A0 (en) Drug delivery system
GB8616617D0 (en) Drug delivery system
GB8601102D0 (en) Bioadhesive drug delivery system
IE872372L (en) Drug delivery system using a block copolymer.
IE862619L (en) Lipoprotein-based drug delivery systems
IE861118L (en) Delivery system for active ingredients
IL97848A0 (en) Passive drug delivery system

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060522